Clinical Trials · NCT02698384

Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg

Name: Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedN/ALanreotide

Phase: N/A
Recruitment status: Terminated
Sponsor: Ipsen
Enrollment: 4
Start date: Jan 2016
Locations: 10 sites, France
Primary endpoint: Percentage of subjects who achieve a safe concentration of random Growth Hormone (GH) (≤2.5 ng/mL) and normal age and sex-matched Insulin-like Growth Factor-1 (IGF-1) concentration of the monotherapy phase.

View Lanreotide compound reference